Naturally-acquired immunity to Neisseria meningitidis group A. (Q38881421)

7 September 2017

Naturally-acquired immunity to Neisseria meningitidis group A. (English)

1 reference

7 September 2017

Neisseria meningitidis

1 reference

Jacob Amir

1

1 reference

7 September 2017

Lesile Louie

series ordinal

2

1 reference

7 September 2017

Dan M Granoff

series ordinal

3

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

7 September 2017

7

1 reference

inferred from page(s)

published in

Vaccine

1 reference

7 September 2017

23

1 reference

7 September 2017

8

1 reference

7 September 2017

977-983

1 reference

Manson Lecture. Meningococcal meningitis in Africa.

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Opportunities for control of meningococcal disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Meningococcal disease and season in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Management of an outbreak of meningococcal meningitis in a Sudanese refugee camp in Northern Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Meningococcal disease in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of Age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Uncloaking the meningococcus: dynamics of carriage and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

7 January 2021

inferred from DOI database lookup

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

7 January 2021

inferred from DOI database lookup

Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.042

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2004.07.042

1 reference

7 September 2017

1 reference